GlassScriptPhysician profile
Artun Aksade
NPI 1508088964
$7,346.50
in general payments reported to CMS, 2019-2025
22 companies · $948 in 2025
The $948 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $13.52 · 2021: $62.21 · 2022: $1,708 · 2023: $816 · 2024: $2,292 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Travel and Lodging: $1,065 · Consulting Fee: $53.00 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.00 |
| Travel and Lodging | $1,065.28 |
| Consulting Fee | $53.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,373.26 | 2019-2025 | Da Vinci Surgical System |
| Davol INC. | $622.24 | 2019-2025 | Phasix Mesh |
| Baxter Healthcare | $614.51 | 2023-2025 | Perclot, Tisseel |
| Integra Lifesciences Corporation | $272.41 | 2022-2023 | Integra, Surgimend, Omnigraft |
| Becton, Dickinson and Company | $197.30 | 2024 | Phasix Mesh |
| Kci USA, INC. | $187.45 | 2019-2023 | Prevena |
| W. L. Gore & Associates, INC. | $165.95 | 2023-2024 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Boston Scientific Corporation | $155.90 | 2024 | |
| Smith+Nephew, INC. | $153.51 | 2019 | |
| Teleflex LLC | $147.06 | 2025 | Titan Sgs Bailout Chuck |
| Haemonetics Corporation | $98.93 | 2022 | |
| Novo Nordisk INC | $68.32 | 2023 | Wegovy |
| Medtronic, INC. | $53.00 | 2025 | Surgidac |
| Ethicon US, LLC | $52.52 | 2023 | Harmonic |
| Conmed Corporation | $50.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $34.26 | 2019-2020 | |
| Lilly USA, LLC | $21.60 | 2025 | Mounjaro |
| Covidien LP | $18.40 | 2019 | |
| Convatec INC. | $17.09 | 2025 | |
| Organogenesis INC. | $14.32 | 2019 | |
| Currax Pharmaceuticals LLC | $14.31 | 2025 | Contrave |
| Paratek Pharmaceuticals, INC. | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Artun Aksade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.